Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients

• Published in: Viruses Vol. 12; no. 12; p. 1390
• Main Authors: Hashem, Anwar M., Algaissi, Abdullah, Almahboub, Sarah A., Alfaleh, Mohamed A., Abujamel, Turki S., Alamri, Sawsan S., Alluhaybi, Khalid A., Hobani, Haya I., AlHarbi, Rahaf H., Alsulaiman, Reem M., ElAssouli, M-Zaki, Hala, Sharif, Alharbi, Naif K., Alhabbab, Rowa Y., AlSaieedi, Ahdab A., Abdulaal, Wesam H., Bukhari, Abdullah, AL-Somali, Afrah A., Alofi, Fadwa S., Khogeer, Asim A., Pain, Arnab, Alkayyal, Almohanad A., Almontashiri, Naif A. M., Ahmad, Bakur Mahmoud, Li, Xuguang
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 04.12.2020; MDPI
• Subjects: anti-N antibodies; Antibodies; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Coronaviruses; COVID-19; COVID-19 - diagnosis; COVID-19 - immunology; COVID-19 infection; COVID19; death; disease severity; Hospitalization; Humans; humoral immunity; Immune response (humoral); Immunity, Humoral; Immunoglobulin G; Immunoglobulin G - blood; Immunoglobulin M; Immunoglobulin M - blood; Infections; Intensive care units; Kinetics; Longitudinal Studies; Morbidity; mortality; Neutralization Tests; neutralizing antibodies; Nucleocapsid Proteins - immunology; Nucleoproteins; Pandemics; Patients; Pneumonia; Proteins; Respiratory diseases; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Severity of Illness Index; Spike Glycoprotein, Coronavirus - immunology; Viral infections; Saudi Arabia; United States > US; China; neutralizing antibodies; SARS-CoV-2; anti-N antibodies; COVID19
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v12121390

The Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2, continues to spread globally with significantly high morbidity and mortality rates. Antigen-specific responses are of unquestionable value for clinical management of COVID-19 patients. Here, we investigated the kinetics of IgM, IgG against the spike (S) and nucleoproteins (N) proteins and their neutralizing capabilities in hospitalized COVID-19 patients with different disease presentations (i.e., mild, moderate or severe), need for intensive care units (ICU) admission or outcomes (i.e., survival vs death). We show that SARS-CoV-2 specific IgG, IgM and neutralizing antibodies (nAbs) were readily detectable in almost all COVID-19 patients with various clinical presentations. Interestingly, significantly higher levels of nAbs as well as anti-S1 and -N IgG and IgM antibodies were found in patients with more severe symptoms, patients requiring admission to ICU or those with fatal outcomes. More importantly, early after symptoms onset, we found that the levels of anti-N antibodies correlated strongly with disease severity. Collectively, these findings provide new insights into the kinetics of antibody responses in COVID-19 patients with different disease severity.